The lipopolysaccharide (LPS), derived from intestinal Gram-negative bacteria, has been widely thought to contribute to the chronic inflammation in diverse metabolic diseases via translocation from the gut barrier and activating an inflammatory cascade in Mψ by binding the TLR-4 (18). This evidence concerns the gene TLR4 and metabolic disease.